EW vs GILD
EW: Global leader in transcatheter heart valve therapies and structural heart repair technologies, treating the world's leading cause of death with minimally invasive solutions. GILD: A diversified biopharmaceutical company pioneering viral disease treatments, cell therapies, and oncology medicines with a portfolio spanning HIV, hepatitis, and cancer.
Side-by-side fundamentals
| Metric | EW | GILD | Edge |
|---|---|---|---|
| Price as of 2026-07-15 close | $87.27 | $131.70 | |
| Market cap as of 2026-07-16 | $50.9B | $164.0B | |
| P/E as of 2026-07-16 | 46.42 | 17.79 | GILD lower |
| PEG as of 2026-07-16 | 2.13 | 1.94 | GILD lower |
| Net margin as of 2026-07-16 | +17.4% | +31.0% | GILD higher |
| Gross margin as of 2026-07-16 | +77.9% | +79.3% | GILD higher |
| Operating margin as of 2026-07-16 | +17.1% | +34.9% | GILD higher |
| ROE as of 2026-07-16 | +10.6% | +42.2% | GILD higher |
| ROA as of 2026-07-16 | +8.2% | +16.1% | GILD higher |
| Debt / equity as of 2026-07-16 | 0.06 | 0.94 | EW lower |
| Revenue growth (YoY) as of 2026-07-16 | +13.8% | +3.5% | EW higher |
| Revenue CAGR (3y) SEC XBRL | +10.8% | +2.6% | EW higher |
| Dividend yield as of 2026-07-16 | n/a | +2.5% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-07-16 | 0.83 | 0.35 | |
| 1-year return as of 2026-07-15 close | +15.1% | +20.8% | GILD higher |
Fundamentals: Finnhub, as of 2026-07-16. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-15.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.